Lifesci Capital Forecasts Disc Medicine FY2025 Earnings

Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Stock analysts at Lifesci Capital issued their FY2025 earnings estimates for shares of Disc Medicine in a report issued on Monday, June 16th. Lifesci Capital analyst R. Katkhuda anticipates that the company will post earnings of ($3.43) per share for the year. The consensus estimate for Disc Medicine's current full-year earnings is ($4.07) per share. Lifesci Capital also issued estimates for Disc Medicine's Q4 2025 earnings at ($1.08) EPS.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.99) by ($0.03).

Several other analysts have also weighed in on IRON. Cantor Fitzgerald lifted their price objective on shares of Disc Medicine from $99.00 to $132.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Scotiabank lifted their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Raymond James Financial began coverage on shares of Disc Medicine in a research report on Wednesday, June 11th. They issued a "strong-buy" rating and a $89.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $118.00 price target on shares of Disc Medicine in a research report on Tuesday. Finally, BMO Capital Markets lifted their price target on shares of Disc Medicine from $112.00 to $120.00 and gave the company an "outperform" rating in a research report on Monday, May 12th. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Disc Medicine has an average rating of "Buy" and a consensus target price of $96.70.

Disc Medicine Trading Up 3.0%

Shares of NASDAQ:IRON traded up $1.52 during mid-day trading on Wednesday, hitting $51.61. The company had a trading volume of 413,971 shares, compared to its average volume of 341,858. The firm has a fifty day moving average price of $47.22 and a 200 day moving average price of $52.80. The company has a market capitalization of $1.79 billion, a PE ratio of -13.17 and a beta of 0.73. The company has a debt-to-equity ratio of 0.04, a current ratio of 37.65 and a quick ratio of 37.65. Disc Medicine has a one year low of $30.82 and a one year high of $68.73.

Hedge Funds Weigh In On Disc Medicine

A number of hedge funds have recently bought and sold shares of the company. Amalgamated Bank boosted its holdings in Disc Medicine by 38.6% during the 1st quarter. Amalgamated Bank now owns 787 shares of the company's stock worth $39,000 after acquiring an additional 219 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock worth $52,000 after buying an additional 266 shares during the last quarter. Teacher Retirement System of Texas boosted its holdings in shares of Disc Medicine by 8.9% in the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after buying an additional 396 shares during the last quarter. Sterling Capital Management LLC boosted its holdings in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock worth $36,000 after buying an additional 503 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in shares of Disc Medicine by 12.5% in the 1st quarter. Arizona State Retirement System now owns 5,315 shares of the company's stock worth $264,000 after buying an additional 590 shares during the last quarter. 83.70% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Disc Medicine news, CFO Jean M. Franchi sold 2,000 shares of Disc Medicine stock in a transaction on Monday, June 16th. The shares were sold at an average price of $52.26, for a total transaction of $104,520.00. Following the transaction, the chief financial officer now directly owns 67,530 shares of the company's stock, valued at $3,529,117.80. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider William Jacob Savage sold 2,100 shares of Disc Medicine stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $50.17, for a total transaction of $105,357.00. Following the transaction, the insider now directly owns 66,398 shares in the company, valued at $3,331,187.66. This represents a 3.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 19,511 shares of company stock valued at $1,004,277 in the last three months. 4.24% of the stock is currently owned by insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.